age-related macular degeneration

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

Outlook slumps as FDA rejects eye disease drug

Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

French court overturns €444m fine for Novartis, Roche

Says companies did not abuse a market position to push Lucentis over off-label Avastin in AMD.

Views & Analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

News

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

Novartis drops geographic atrophy gene therapy

Outlook slumps as FDA rejects eye disease drug

Astellas cuts $5.9bn deal to buy Iveric Bio

French court overturns €444m fine for Novartis, Roche

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

age-related macular degeneration

Editor's Picks